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Reduction in Overall Occurrences of Ischemic Events With Vorapaxar:
Results From TRACER
Harvey D. White, DSc; Zhen Huang, MS; Pierluigi Tricoci, MD, MHS, PhD; Frans Van de Werf, MD; Lars Wallentin, MD, PhD;
Yuliya Lokhnygina, PhD; David J. Moliterno, MD; Philip E. Aylward, MD; Kenneth W. Mahaffey, MD; Paul W. Armstrong, MD
Background-—Clinical trials traditionally use time-to-first-event analysis embedded within the composite endpoint of cardiovas-
cular death (CVD), myocardial infarction (MI), or stroke. However, many patients have >1 event, and this approach may not reflect
overall experience. We addressed this by analyzing all cardiovascular events in TRACER.
Methods and Results-—TRACER randomized 12 944 patients with non-ST-segment elevation acute coronary syndromes to
placebo or to protease-activated receptor 1 antagonist vorapaxar with a median follow-up of 502 days (interquartile range, 349 to
667). Analysis of vorapaxar’s effect on recurrent CVD, MI, or stroke was prespecified using the Wei, Lin, and Weissfeld approach.
Vorapaxar did not reduce the first occurrence of the primary endpoint of CVD, MI, stroke, revascularization, or rehospitalization for
recurrent ischemia, but reduced the secondary composite endpoint of CVD, MI, or stroke (14.7% vorapaxar vs. 16.4% placebo;
hazard ratio [HR], 0.89; 95% confidence interval [CI], 0.81 to 0.98; P=0.02; number needed to treat [NNT], 81). Recurrent
secondary events occurred in 2.7% of patients. Vorapaxar reduced overall occurrences of ischemic events, first and subsequent
(HR, 0.88; 95% CI, 0.80 to 0.98; P=0.02; NNT, 51). Also, there was a trend indicating that vorapaxar reduced the expanded
endpoint, including revascularization and rehospitalization for recurrent ischemia (HR, 0.92; 95% CI, 0.84 to 1.01; P=0.09).
Vorapaxar increased overall occurrences of moderate and severe Global Use of Strategies to Open Occluded Coronary Arteries
bleeding (HR, 1.42; 95% CI, 1.21 to 1.66; P<0.001) and Thrombolysis in Myocardial Infarction clinically significant bleeding (HR,
1.550; 95% CI, 1.403 to 1.713; P<0.001).
Conclusions-—Vorapaxar reduced overall occurrences of ischemic events, but increased bleeding. These exploratory findings
broaden our understanding of vorapaxar’s potential and expand our understanding of the value of capturing recurrent events.
Clinical Trial Registration-—URL: ClinicalTrials.gov. Unique identifier: NCT00527943. ( J Am Heart Assoc. 2014;3:e001032 doi:
10.1161/JAHA.114.001032)
Key Words: acute coronary syndromes • recurrent events • vorapaxar
M ost clinical trials incorporate “time to first event” intotheir primary analyses and do not take into account
the effect of therapy after the initial event. Therefore, the
disease burden and effectiveness and safety of a therapy may
not represent the totality of the patient experience. The
Thrombin Receptor Antagonist for Clinical Event Reduction in
Acute Coronary Syndrome (TRACER) trial randomized nearly
13 000 patients with non-ST-segment elevation acute coro-
nary syndromes (NSTE ACS) to the protease-activated recep-
tor 1 antagonist vorapaxar or placebo. The study was
terminated prematurely, after enrollment completion and the
target endpoint was reached, following an unplanned, inde-
pendent safety review of excess bleeding hazard. Randomi-
zation to vorapaxar was associated with no significant effect
on the first occurrence of the primary composite endpoint of
cardiovascular death (CVD), myocardial infarction (MI), stroke,
recurrent ischemia with rehospitalization, or urgent coronary
revascularization (hazard ratio [HR], 0.92; 95% confidence
interval [CI], 0.85 to 1.01; P=0.07). There was, however, a
nominal reduction of the prespecified, secondary, time-to-
event composite endpoint of CVD, MI, or stroke (HR, 0.89;
95% CI, 0.81 to 0.98; P=0.02).1,2
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In the current report, we further explored the effect of
randomized treatment with placebo or vorapaxar on overall
event history of CVD, MI, or stroke. We also explored the
effect of treatment on overall occurrences of bleeding
events.
Methods
The TRACER trial’s design,3 endpoint definitions, and primary
results have been reported.2 In summary, this double-blind,
placebo-controlled, event-driven, international trial in 37
countries compared placebo with vorapaxar (40-mg loading
dose followed by 2.5 mg daily) in patients with NSTE ACS at
high risk for ischemic events. Patients were planned to be
followed for at least 1 year. All patients who experienced
nonfatal events were recommended to continue the random-
ized treatment.
The TRACER study was approved by institutional review
committees and all patients gave informed consent.
Statistical Analysis
We analyzed overall occurrences of the composite ischemic
endpoints and composite bleeding endpoints as described
above. As prespecified in the protocol, analyses of efficacy
endpoints included all randomized subjects with events
accrued from randomization to last follow-up. Analyses of
bleeding endpoints included subjects with at least 1 dose
of randomized treatment with events accrued while on
treatment.
Baseline characteristics were presented for patients who
experienced none, 1, or multiple composite endpoints. To
investigate the effect of vorapaxar on occurrences of events,
we employed the stratified Cox model proposed by Wei, Lin,
and Weissfeld (the WLW model).4 The WLW model allows us to
consider the ordering of events as separate events (ie, strata)
of interest, as well as the different types of events that may
occur in the same patient (eg, MI or stroke). A subject is
simultaneously included in the model for time to first event of
interest, time to second event of interest, etc., up to the
maximum number of events observed for a subject in a study.
In the model for time to Kth event (K=1, 2, etc.), a subject’s
time starts at randomization and ends at either (1) the time
when the subject’s Kth event has occurred or (2) the time of
death or last follow-up. In the latter case, the subject would
be censored. With this approach, we investigated the effect of
vorapaxar on the first and each subsequent event as well as
the common treatment effect across the entire event history.
In addition, we estimated the number needed to treat (NNT)
all events as well as the first event. HRs and corresponding
CIs are reported.
Multivariable analyses were carried out to identify
patients who were at risk of having >1 event. Baseline
characteristics, randomized treatment, and interactions
between the 2 treatment groups were included in the model
(Appendices A and B). Factors were selected through
forward, backward, and step-wise selection processes. P
values were not adjusted for multiple comparisons. Analyses
were performed using SAS software (version 9.0; SAS
Institute Inc., Cary, NC).
Results
The flow of patients in the TRACER trial and the occurrences
of single and recurrent events are shown in Figure 1. The key
secondary composite endpoint of CVD, MI, or stroke occurred
Figure 1. Patient flows and occurrences of ischnemic events. MI indicates myocardial
infarction.
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in 822 of 6473 patients (12.7%) receiving vorapaxar versus
910 of 6471 patients (14.1%) receiving placebo (HR, 0.89;
95% CI, 0.81 to 0.98; P=0.02) during the follow-up period of
502 days (interquartile range, 349 to 667).
Single Occurrence
As noted in Table 1 and Figure 1, the number of patients with
just 1 occurrence of the composite endpoint of CVD, MI, or
Table 1. Baseline Characteristics for Patients With No Occurrence, a Single Occurrence, or Multiple Occurrences of Key
Secondary Endpoints
No Occurrence (n=11 212) Single Occurrence (n=1384) Multiple Occurrence (n=348)
Age, y, mean (SD) 64.1 (9.8) 66.0 (10.4) 68.5 (10.3)
Female, n (%) 3127 (27.9) 406 (29.3) 99 (28.4)
Race (%)
White 9589/11 181 (85.8) 1156/1381 (83.7) 294/347 (84.7)
Black 256/11 181 (2.3) 46/1381 (3.3) 10/347 (2.9)
American Indian 29/11 181 (0.3) 5/1381 (0.4) 1/347 (0.3)
Asian 925/11 181 (8.3) 105/1381 (7.6) 26/347 (7.5)
Pacific Islander 27/11 181 (0.2) 4/1381 (0.3) 1/347 (0.3)
Multiracial 355/11 181 (3.2) 65/1381 (4.7) 15/347 (4.3)
Region (%)
North America 2855/11 212 (25.5) 425/1384 (30.7) 124/348 (35.6)
Latin America 709/11 212 (6.3) 112/1384 (8.1) 27/348 (7.8)
Europe I 5142/11 212 (45.9) 575/1384 (41.5) 122/348 (35.1)
Europe II 1319/11 212 (11.8) 135/1384 (9.8) 33/348 (9.5)
Asia 822/11 212 (7.3) 90/1384 (6.5) 24/348 (6.9)
Australia/New Zealand 365/11 212 (3.3) 47/1384 (3.4) 18/348 (5.2)
Body weight, kg, mean (SD) 82.5 (17.7) 82.5 (18.9) 81.9 (18.7)
BMI*, mean (SD) 28.5 (5.2) 28.8 (5.7) 28.8 (5.3)
Hypertension (%) 7776/11 207 (69.4) 1060/1384 (76.6) 292/348 (83.9)
Hyperlipidemia (%) 6877/11 204 (61.4) 928/1384 (67.1) 257/348 (73.9)
Diabetes mellitus (%) 3319/11 206 (29.6) 578/1384 (41.8) 173/348 (49.7)
Previous stroke (%) 427/11 207 (3.8) 88/1384 (6.4) 38/348 (10.9)
Previous myocardial infarction (%) 3067/11 206 (27.4) 536/1384 (38.7) 188/348 (54.0)
Peripheral arterial vascular disease (%) 692/11 205 (6.2) 173/1384 (12.5) 71/348 (20.4)
Past tobacco use (%) 3590/11 205 (32.0) 456/1384 (32.9) 140/348 (40.2)
Current tobacco use (%) 3106/11 205 (27.7) 363/1384 (26.2) 67/348 (19.3)
Percutaneous coronary intervention (%) 2534/11 202 (22.6) 421/1384 (30.4) 135/348 (38.8)
Coronary artery bypass graft (%) 1165/11 207 (10.4) 256/1384 (18.5) 122/348 (35.1)
Statin at enrollment (%) 9399/11 212 (83.8) 1169/1384 (84.5) 304/348 (87.4)
Thienopyridine at enrollment (%) 9788/11 212 (87.3) 1212/1384 (87.6) 307/348 (88.2)
Troponin or CK-MB positive (%) 10 397/11 133 (93.4) 1322/1377 (96.0) 331/347 (95.4)
Renal insufficiency <30 mL/min (%) 124/10 622 (1.2) 37/1306 (2.8) 29/333 (8.7)
ST-segment depression (%) 3562/11 212 (31.8) 485/1384 (35.0) 152/348 (43.7)
ST-segment elevation (%) 637/11 212 (5.7) 76/1384 (5.5) 23/348 (6.6)
TIMI risk score ≥3 (%) 11 149/11 212 (99.4) 1380/1384 (99.7) 348/348 (100.0)
Data presented as n/N (%), unless otherwise indicated. CK-MB indicates creatine kinase-MB; TIMI, Thrombolysis in Myocardial Infarction.
*Weight (kg)/height2 (m2).
DOI: 10.1161/JAHA.114.001032 Journal of the American Heart Association 3















 at University of Kentucky--Lexington on February 16, 2016http://jaha.ahajournals.org/Downloaded from 
stroke was 1384 (652 vorapaxar [10.1%] and 732 placebo
[11.3%]; odds ratio, 0.8765; 95% CI, 0.7838 to 0.9803;
P=0.03).
Multiple Occurrences
As shown in Tables 1 and 2, patient characteristics associ-
ated with increased occurrences of CVD, MI, and stroke
events were older age; having diabetes; history of hyperten-
sion (HTN), MI, or stroke; peripheral arterial vascular disease;
impaired renal function; previous percutaneous coronary
intervention and coronary artery bypass grafting; and taking
thienopyridine or statins at baseline. Most factors associated
with risk for first ischemic event were also associated with
recurrent events. As shown in Table 3, there were more
patients with HTN and more current smokers in the placebo
group.
Multiple recurrent events of CVD, MI, and stroke occurred
in 2.6% of patients randomized to vorapaxar and in 2.8% of
patients randomized to placebo. Overall, patients randomized
to vorapaxar experienced fewer occurrences of events during
the study than patients randomized to placebo (HR, 0.88; 95%
CI, 0.80 to 0.98; P=0.02; NNT, 51). Recurrent MI occurred
in 86 (1.3%) of vorapaxar and 101 (1.6%) placebo patients,
whereas recurrent stroke occurred in 4 (<0.1%) vorapaxar and
10 (0.15%) placebo patients. Table 4 shows that there is a
nonsignificant effect of vorapaxar on overall occurrences of
the expanded composite endpoint (HR, 0.92; 95% CI, 0.84 to
1.01; P=0.09; NNT, 62).
Sequence of Events
Table 5 shows the sequences of events in the order they
occurred for patients whose first event was MI or stroke.
Figure 2 shows the total number of events for patients whose
first events were CVD, MI, or stroke. CVD occurred as a first
event in 202 vorapaxar patients (3.1%) and in 208 placebo
patients (3.2%). Nonfatal MI or nonfatal stroke occurred
before CVD in 170 patients (1.3%), with 90 (1.4%) in the
vorapaxar group, and 80 (1.2%) in the placebo group.
Recurrence of the expanded endpoint, including revascu-
larization and rehospitalization for recurrent ischemia,
occurred in 237 (3.7%) vorapaxar and 449 (6.9%) placebo
patients. Figure 3 shows the first and second events with the
expanded endpoint. Recurrent revascularization occurred in
14 vorapaxar and 14 placebo patients, and recurrent hospi-
talization for recurrent ischemia occurred in 4 vorapaxar and 2
placebo patients.
Table 2. Baseline Characteristics Associated With Multiple Occurrences of CVD, MI, or Stroke
HR (95% CI) P Value
Heart rate by 10/min 1.079 (1.035 to 1.124) 0.0003
Age ≥75 years 1.461 (1.258 to 1.697) <0.0001
Multirace 1.417 (1.081 to 1.857) 0.0115
Region: North America 1.298 (1.144 to 1.473) <0.0001
History of hypertension 1.156 (1.012 to 1.321) 0.0323
History of diabetes mellitus 1.378 (1.228 to 1.546) <0.0001
History of stroke 1.266 (1.023 to 1.568) 0.0302
History of myocardial infarction 1.377 (1.201 to 1.580) <0.0001
History of peripheral arterial vascular disease 1.595 (1.359 to 1.872) <0.0001
History of percutaneous coronary intervention 1.160 (1.012 to 1.330) 0.0334
History of coronary artery bypass grafting 1.713 (1.479 to 1.983) <0.0001
Qualifying event: troponin or CK-MB >upper limit of normal 1.670 (1.254 to 2.224) 0.0004
ST-segment elevation at enrollment 1.254 (0.991 to 1.587) 0.0598
ST-segment depression at enrollment 1.384 (1.232 to 1.556) <0.0001
Renal insufficiency: CrCl <30 mL/min 2.459 (1.818 to 3.325) <0.0001
Renal insufficiency: CrCl ≤30 to <60 mL/min 1.382 (1.174 to 1.627) 0.0001
Killip scale I 0.600 (0.500 to 0.722) <0.0001
Taking thienopyridine at enrollment 1.191 (1.000 to 1.419) 0.0505
Taking statin at enrollment 1.193 (1.027 to 1.384) 0.0206
CI indicates confidence interval; CK-MB, creatine kinase-MB; CrCl, creatinine clearance; CVD, cardiovascular death; HR, hazard ratio; MI, myocardial infarction.
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Study drug discontinuation was slightly higher in the
vorapaxar group, compared to the placebo group (28.2% vs.
26.8%; P=0.07).
Safety
Vorapaxar increased Global Use of Strategies to Open
Occluded Coronary Arteries (GUSTO) moderate and severe
bleeding overall (Table 6; HR, 1.42; 95% CI, 1.21 to 1.66;
P<0.001). Recurrent GUSTO moderate or severe bleeding
occurred in 0.3% of patients, and a second occurrence of
Thrombolysis in Myocardial Infarction (TIMI) clinically signif-
icant bleeding occurred in 1.7%, a third occurrence in 0.3%,
a fourth in 0.04%, and a fifth in 0.02%. Vorapaxar also
increased TIMI clinically significant bleeding (1.55; 95% CI,
1.40 to 1.71; P<0.001). Table 7 shows the effect of
vorapaxar on overall occurrences of TIMI clinically significant
bleeding.
Discussion
In TRACER patients with NSTE ACS, a single component of the
key secondary composite endpoint of CVD, MI, or stroke in
the time-to-first-event analysis occurred in 10.7% of patients.
Multiple recurrent events occurred in 2.7% of patients,
meaning that 25.2% of patients included in the time-to-first-
event analysis had recurrent events. Vorapaxar reduced first
events by 11% (HR, 0.89; 95% CI, 0.81 to 0.98) and overall
ischemic events by 12% (HR, 0.88, 95% CI, 0.80 to 0.98).
The effect of vorapaxar on the reduction of total events
was greater than previously reported for time-to-first-event
analysis,2 with the NNT over 502 days reduced from 81 to 51
for the composite endpoint of CVD, MI, or stroke. These data
Table 3. Baseline Characteristics According to Randomized
Treatments for Patients Who Had Multiple Occurrences of
CVD, MI, or Stroke
Vorapaxar (n=170) Placebo (n=178)
Age, y, mean (SD) 69.6 (10.3) 67.6 (10.2)
Age ≥75 years (%) 61/170 (35.9) 52/178 (29.2)
Female (%) 42/170 (24.7) 57/178 (32.0)
Race (%)
White 140/170 (82.4) 154/177 (87.0)
Black 3/170 (1.8) 7/177 (4.0)
American Indian 1/170 (0.6) 0/177 (0.0)
Asian 15/170 (8.8) 11/177 (6.2)
Pacific Islander 1/170 (0.6) 0/177 (0.0)
Multiracial 10/170 (5.9) 5/177 (2.8)
Body weight (kg), mean (SD) 81.3 (18.1) 82.5 (19.2)
BMI*, mean (SD) 28.7 (5.1) 28.9 (5.5)
Hypertension (%) 135/170 (79.4) 157/178 (88.2)
Hyperlipidemia (%) 125/170 (73.5) 132/178 (74.2)
Diabetes mellitus (%) 85/170 (50.0) 88/178 (49.4)
Stroke (%) 19/170 (11.2) 19/178 (10.7)
Myocardial infarction (%) 88/170 (51.8) 100/178 (56.2)
Peripheral arterial
vascular disease (%)
40/170 (23.5) 31/178 (17.4)
Past tobacco use (%) 77/170 (45.3) 63/178 (35.4)
Current tobacco use (%) 23/170 (13.5) 44/178 (24.7)
Percutaneous coronary
intervention (%)
64/170 (37.6) 71/178 (39.9)
Coronary artery
bypass graft (%)
59/170 (34.7) 63/178 (35.4)
Statin at enrollment (%) 146/170 (85.9) 158/178 (88.8)
Thienopyridine at
enrollment (%)
154/170 (90.6) 153/178 (86.0)
Troponin or CK-MB
positive (%)
165/170 (97.1) 166/177 (93.8)
Renal insufficiency
CrCl <30 mL/min (%)
19/164 (11.6) 10/169 (5.9)
ST-segment depression (%) 79/170 (46.5) 73/178 (41.0)
ST-segment elevation (%) 11/170 (6.5) 12/178 (6.7)
Killip class >II (%) 11/169 (6.5) 8/178 (4.5)
TIMI risk score ≥3 (%) 170/170 (100.0) 178/178 (100.0)
Data presented as n/N (%), unless otherwise noted. BMI indicates body mass index;
CK-MB, creatine kinase-MB; CrCl, creatinine clearance; CVD, cardiovascular death;
MI, myocardial infarction; TIMI, Thrombolysis in Myocardial Infarction.
*Weight (kg)/height2 (m2).
Table 4. Effect of Vorapaxar on Overall Occurrences of
the Composite Endpoint of CVD, MI, Stroke, Urgent
Revascularization, and Rehospitalization for Ischemic Event
WLW Marginal Regression Model of All Occurrences of Events
Parameter HR (95% CI) Pr>Chi-Square
Vorapaxar effect on
First event 0.924 (0.849 to 1.006) 0.0695
Second event 1.001 (0.836 to 1.199) 0.9892
Third event 0.901 (0.634 to 1.282) 0.5635
Fourth event 0.618 (0.309 to 1.236) 0.1737
Fifth event 0.272 (0.076 to 0.973) 0.0452
Sixth event 0.000 (0.000 to 0.000) <0.0001
Seventh event 0.000 (0.000 to 0.000) <0.0001




0.921 (0.837 to 1.012) 0.0884
CI indicates confidence interval; CVD, cardiovascular death; HR, hazard ratio;
MI, myocardial infarction; WLW, Wei, Lin, and Weissfeld.
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show the importance of capturing recurrent events to
ascertain overall patient benefit.
Vorapaxar increased moderate and severe bleeding overall
as well as recurrent GUSTO moderate and severe bleeding
and TIMI clinically significant bleeding. However, recurrent
bleeding was infrequent, with 0.4% of patients receiving
vorapaxar having a recurrent GUSTO moderate-to-severe
bleed and 2.9% having a recurrent TIMI clinically significant
bleed, despite continuing therapy in most patients. Among
patients who had GUSTO moderate or severe bleeding, 62% of
them (60% of vorapaxar and 67% of placebo) never discon-
tinued treatment. Among patients who had TIMI clinically
significant bleeding, 69% (67% vorapaxar and 73% placebo)
never discontinued treatment. As a reference, among those
who never had a bleeding event, 74% (73% vorapaxar and 74%
placebo) never discontinued treatment.
These findings increase our understanding of the overall
benefit of vorapaxar in addition to treatment with aspirin in
patients with NSTE ACS. Clearly, reducing recurrent events is
of major clinical benefit. In addition, reducing the total burden
of ischemic events may also reduce costs,5–8 but must be
balanced with the increased bleeding.
Combination and Sequence of Events
With a composite endpoint of CVD, MI, or stroke, there are
7 possible sequences of events if only 1 event of each type
occurs. If multiple MI or stroke events occur, there are
many more possibilities, as shown in Table 5. Patients had
up to 7 recurrences of MI and 3 had recurrence of 2
strokes. There was a high dependence of recurrent events,
with nonfatal MI or nonfatal stroke occurring before CVD in
1.3% of patients. This stresses the importance of continuing
vorapaxar and other therapies when a patient experiences
nonfatal events.
Factors associated with increased occurrence of events
included most risk factors for ischemic events. Taking a
thienopyridine or a statin at enrollment was associated with
increased occurrence of events. Other studies with P2Y12
inhibitors have shown the efficacy of prasugrel and ticagrelor
in reducing recurrent events, as compared with clopidogrel
treatment.6,9 In the PLATelet inhibition and patient Outcomes
(PLATO) trial, ticagrelor reduced first and recurrent events, as
compared with clopidogrel (HR for time to second event, 0.80;
95% CI, 0.70 to 0.90; P<0.001).6 Most of the treatment effect
(83%) was expressed with first events in the composite
endpoint of CVD, MI, or stroke. In the Trial to Assess
Improvement in Therapeutic Outcomes by Optimizing Platelet
Inhibition with Prasugrel/Thrombolysis in Myocardial Infarc-
tion (TRITON-TIMI) trial, prasugrel reduced subsequent events
among patients who survived the primary event, as compared
with patients taking clopidogrel (HR, 0.65; 95% CI, 0.46 to
0.92; P=0.016).9 Again, most of the treatment effect (70.8%)
was on the primary composite endpoint of CVD, MI, or stroke.
In the current analysis, the effect of vorapaxar on recurrent
events was also mostly on first events (1732 of 2080 first
events=83.3%).
Limitations
The WLW survival analysis we used for assessment of
recurrent events is well validated,10,11 but the statistical
model has a number of limitations, including that the
evaluation of treatment effect on recurrent events includes
the treatment effect on first events and does not preserve the
initial randomization. Recurrent event analyses are also
affected by different mortality rates and other postrandom-
ization factors in the 2 randomized treatment groups. Only the
former was accounted for by the WLW method. We did not
collect information about the size of the recurrent MIs or the
disability associated with recurrent strokes.
Table 5. Sequence of Ischemic Events in the Order They
Occurred
Sequence of Events Placebo Vorapaxar Total
Subjects whose first event was MI
MI_CVD 44 (0.68) 49 (0.76) 93
MI_MI_CVD 10 (0.15) 14 (0.22) 24
MI_MI_MI_CVD 4 (0.06) 3 (0.05) 7
MI_MI_MI_MI_CVD 1 (0.02) 0 (0.00) 1
MI_MI_MI_MI_MI_CVD 1 (0.02) 0 (0.00) 1
MI_MI 51 (0.79) 43 (0.66) 94
MI_MI_MI 9 (0.14) 10 (0.15) 19
MI_MI_MI_MI 2 (0.03) 5 (0.08) 7
MI_MI_MI_MI_MI 1 (0.02) 0 (0.00) 1
MI_MI_MI_MI_MI_MI_MI_MI 1 (0.02) 0 (0.00) 1
MI_stroke 7 (0.11) 6 (0.09) 13
MI_stroke_MI 2 (0.03) 0 (0.00) 2
MI_stroke_CVD 2 (0.03) 1 (0.02) 3
Subjects whose first event was stroke
Stroke_CVD 7 (0.11) 10 (0.15) 17
Stroke_MI 4 (0.06) 4 (0.06) 8
Stroke_MI_CVD 1 (0.02) 1 (0.02) 2
Stroke_MI_MI 0 (0.00) 1 (0.02) 1
Stroke_stroke 4 (0.06) 3 (0.05) 7
Stroke_stroke_CVD 2 (0.03) 1 (0.02) 3
Stroke_stroke_MI 1 (0.02) 0 (0.00) 1
Stroke_stroke_stroke 3 (0.05) 0 (0.00) 3
Data presented as n (%). CVD indicates cardiovascular death; MI, myocardial infarction.
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Figure 2. First and subsequent CVD, MI, or stroke among patients randomized to vorapaxar
or to placebo. CVD indicates cardiovascular death; MI, myocardial infarction; rehosp,
rehospitalization; revasc, revascularization.
Figure 3. First and second ischemic events, CVD, MI, or stroke among patients randomized
to vorapaxar or to placebo. CVD indicates cardiovascular death; MI, myocardial infarction;
rehosp, rehospitalization; revasc, revascularization.
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In this analysis, each of the components of the composite
endpoint (CVD, MI, or stroke) was weighted equally. However,
the relative importance of the components of the composite
may differ between clinical trialists,12 physicians, and
patients, and more research is required in this area.
Conclusions
Randomization to vorapaxar nominally reduced the time to first
composite event of CVD, MI, or stroke and the risk of recurrent
ischemic events. The NNT was reduced from 81 for first events
to 51 for recurrent events. Overall recurrent moderate and
severe GUSTO bleeding aswell as recurrent clinically significant
TIMI bleeding was increased with vorapaxar. These exploratory
findings increase our knowledge of the overall potential of
vorapaxar to reduce ischemic events and of its safety.
Focusing only on time-to-first-event analysis may miss
important information about efficacy and risks of a therapy.
Appendix A
Baseline Covariates for Ischemic Events
Demographics: age, sex, and race; vital signs: weight, heart
rate, and diastolic blood pressure; medical history: hyperten-
sion, diabetes, stroke, transient ischemic attack, angina,
myocardial infarction, peripheral artery disease, heart failure,
atrial fibrillation, tobacco use, percutaneous coronary inter-
vention, and coronary artery bypass graft; disease status at
enrollment: ST-segment elevation, new T wave, and Killip
class; labs at enrollment: troponin and creatinine clearance;
medications at baseline: thienopyridine, aspirin, beta-blocker,
statin, and glycoprotein IIb/IIIa.
Appendix B
Baseline Covariates for Bleeding Events
Demographics: age, sex, and race; vital signs: weight, heart
rate, and diastolic blood pressure; medical history: hyperten-
sion, diabetes, stroke, transient ischemic attack, angina,
myocardial infarction, peripheral artery disease, heart failure,
atrial fibrillation, tobacco use, percutaneous coronary inter-
vention, and coronary artery bypass graft; disease status at
enrollment: ST-segment elevation, new T wave, and Killip class;
labs at enrollment: troponin, creatinine clearance, hemoglobin,
and white blood cells; medications at baseline: thienopyridine,
aspirin, beta-blocker, statin, and glycoprotein IIb/IIIa.
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Table 6. Patients With Occurrences of Bleeding Endpoints
and Their Components
Vorapaxar (n=6446) (%) Placebo (n=6441) (%)
Patients with occurrence of GUSTO moderate or severe bleeding
1 362 (5.6) 274 (4.3)
2 27 (0.4) 16 (0.2)
3 2 (0.03) 0 (0.0)
Patients with occurrence of TIMI clinically significant bleeding
1 878 (13.6) 678 (10.5)
2 149 (2.3) 66 (1.0)
3 30 (0.5) 11 (0.2)
4 5 (0.08) 0 (0.0)
5 3 (0.05) 0 (0.0)
Data presented as n (%). GUSTO indicates Global Use of Strategies to Open Occluded
Coronary Arteries; TIMI, Thrombolysis in Myocardial Infarction.
Table 7. Effect of Vorapaxar on Overall Occurrences of
Composite TIMI Clinically Significant Bleeding Event
WLW Marginal Regression Model of All Occurrences of TIMI Clinically Significant
Bleeding Events
Parameter HR (95% CI) Pr>Chi-Square
Vorapaxar effect on
First event 1.427 (1.300 to 1.566) <0.0001
Second event 2.428 (1.865 to 3.162) <0.0001
Third event 3.207 (1.678 to 6.129) 0.0004
Fourth event 8.050 (1.002 to 64.654) 0.0498
Fifth event 3.049 (0.312 to 29.796) 0.3379
Sixth event 0.000 (0.000 to 0.001) <0.0001
Common vorapaxar
effect across all events
1.550 (1.403 to 1.713) <0.0001
CI indicates confidence interval; HR, hazard ratio; TIMI, Thrombolysis in Myocardial
Infarction; WLW, Wei, Lin, and Weissfeld.
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